肿瘤防治研究2024，Vol.51Issue(3)：191-194,4.DOI:10.3971/j.issn.1000-8578.2024.23.0909
赛沃替尼在Ⅲ/IV期非小细胞肺癌中的疗效观察
Therapeutic Effect of Savolitinib in Patients with Stage Ⅲ/Ⅳ Non-small Cell Lung Cancer
钟诚 1张扬 1储子昂 1钱洪1
作者信息
- 1. 246004 安庆,海军安庆医院肿瘤中心
- 折叠
摘要
Abstract
Objective To analyze therapeutic effect of savolitinib in patients with stage Ⅲ/Ⅳ non-small cell lung cancer(NSCLC).Methods A total of 95 patients with MET 14 exon(METex14)jumping mutation in stage Ⅲ/Ⅳ NSCLC were divided into a control group(47 cases)and an observation group(48 cases)through a random-number table method.The patients in the control group were treated with crizotinib,whereas those in the observation group were treated with savolitinib.The clinical efficacy and incidence of toxic side effects in both groups were evaluated through a chi-square test,and survival was evaluated through Kaplan-Meier survival analysis.Results Compared with control group(31.91％and 70.21％),the objective response rate and disease control rate of the observation group were 52.08％and 87.50％,respectively(P＜0.05).According to Kaplan-Meier survival analysis,the overall survival and progression free survival rates in the observation group were higher than those in the control group(Log rank x2=8.003,4.528;P=0.005,0.033).No statistically significant difference in the degree of toxic side effects was found between the groups(P＞0.05).Conclusion Savolitinib can improve the efficacy of treatment for stage Ⅲ/Ⅳ METex14 skip mutation NSCLC patients,prolong survival,enhance the tolerance of patients to savolitinib,and facilitate the management of adverse reactions.关键词
非小细胞肺癌/间质-上皮细胞转化因子/赛沃替尼Key words
Non-small cell lung cancer/Mesenchymal-epithelial transition factor/Savolitinib分类
医药卫生引用本文复制引用
钟诚,张扬,储子昂,钱洪..赛沃替尼在Ⅲ/IV期非小细胞肺癌中的疗效观察[J].肿瘤防治研究,2024,51(3):191-194,4.
